Evidence map›Paper›PMID 36896217›Full record

ArticleAdvances in radiation oncology

Outcomes and Prognostic Factors for Locally Recurrent Rectal Cancer Treated With Proton Beam Therapy.

Yoshiaki Takagawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Yusuke Azami, Masanori Machida, Kanako Takayama, Takuya Tominaga, Masao Murakami

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yoshiaki TakagawaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Motohisa SuzukiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Hisashi YamaguchiDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Ichiro SetoDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Yusuke AzamiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Masanori MachidaDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Kanako TakayamaDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Takuya TominagaDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Masao MurakamiDepartment of Radiation Oncology, Southern TOHOKU Proton Therapy Center, Fukushima, Japan.
Southern Tohoku General Hospital · JPFukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Our objective was to report the outcome and prognostic factors for patients with locally recurrent rectal cancer (LRRC) treated with proton beam therapy (PBT) at our institution. Methods and Materials: The study included PBT-treated patients with LRRC between December 2008 and December 2019. Treatment response was stratified using an initial imaging test after PBT. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using the Kaplan-Meier method. Each outcome's prognostic factors were verified using the Cox proportional hazards model. Results: Twenty-three patients were enrolled (median follow-up, 37.4 months). There were 11 patients with complete response (CR) or complete metabolic response (CMR), 8 with partial response or partial metabolic response, 2 with stable disease or stable metabolic response, and 2 with progressive disease or progressive metabolic disease. Three- and 5-year OS, PFS, and LC were 72.1% and 44.6%, 37.9% and 37.9%, and 55.0% and 47.2%, respectively, with 54.4 months' median survival time. The maximum standardized uptake value of fluorine-18-fluorodeoxyglucose-positron emission tomography-computed tomography ( Conclusions: The results showed that PBT may have potential to be a good treatment option for LRRC.

Identifiers

PMID36896217
PMCPMC9991532
OpenAlexW4319303442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.